Paradigm’s strategic management is driven by a team with significant experience in drug development and the execution of clinical studies.
Paradigm’s execution of this strategy is driven by a team with significant experience in drug development and performing clinical studies including:
Our Non-Executive Chairman, Mr Graeme Kaufman, has broad experience in the development and commercialisation of pharmaceutical drugs (prior executive roles including CFO at CSL Limited, executive VP of Mesoblast Ltd).
Our Chief Executive Officer, Mr Paul Rennie, has been involved in drug development and a number of pre-clinical and clinical trial programs (was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd). Mr. Rennie has extensive experience in commercialising Intellectual Property.
Our Chief Scientific Officer, Dr Ravi Krishnan, is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell therapy. He has also had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic properties.
Our CFO and Company Secretary, Mr Kevin Hollingsworth, has previous experience with publicly listed biopharmaceutical start-ups such as Mesoblast Ltd and Patrys Ltd.
Our Chief Operations Officer, Dr Claire Kaufman, is an experienced Veterinary Surgeon. After 8 years of clinical veterinary and organisational experience in private practice and animal welfare organisations, Claire pursued work in pre-clinical Immunology research and was responsible for co-ordinating preclinical therapeutic trials. Claire also has extensive experience with the use of Pentosan Polysulphate Sodium (PPS) in clinical veterinary practice.